Subanalysis comparing the GC-peri-tumor and GC-body samples in intestinal-type cancers (n = 11) revealed a significant difference between the percentage of CD8+/CD3+ cells in the GC-peri-tumor samples (76.4 ± 14.3%) and that of the GC-body samples (61.2 ± 14.4%) (Figure 7 in Appendices). This evidence concerns the gene CD8A and cancer.